Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Stock Traders Daily
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

bluebird bio Inc announces pricing of public offering of common stock

Tuesday, 8 Jul 2014 06:58pm EDT 

bluebird bio Inc:Prices underwritten public offering of 3,000,000 shares of its common stock at public offering price of $34.00 per share, before underwriting discounts.In addition, bluebird bio has granted underwriters a 30-day option to purchase from it up to additional 450,000 shares of common stock.BofA Merrill Lynch, Cowen and Company and Citigroup are acting as joint book-running managers of proposed offering.Wedbush PacGrow Life Sciences and SunTrust Robinson Humphrey are acting as co-managers.Offering is expected to close on or about July 14.Anticipates aggregate net proceeds from the offering will be about $95.6 mln, after deducting the underwriting discount and estimated offering expenses payable by bluebird bio, but excluding any exercise of the underwriters' option.Intends to use net proceeds of this offering primarily to advance its clinical studies in CCALD (childhood cerebral adrenoleukodystrophy), beta-thalassemia major and sickle cell disease.Balance will be used for general and administrative expenses, potential future development programs, early-stage research and development and other general corporate purposes.